Alnylam Netherlands

Company snapshot

Alnylam Netherlands maintains 84 tracked programs across TTR-mediated Amyloidosis, Hypertension, Transthyretin Amyloidosis, Type 2 Diabetes Mellitus (T2DM), Acute Intermittent Porphyria, Primary Hyperoxaluria Type 1 (PH1), Transthyretin (TTR)-Mediated Amyloidosis, Transthyretin Amyloidosis (ATTR) With Cardiomyopathy, Huntington’s disease, Hereditary Transthyretin Amyloidosis, Hereditary Transthyre

• 4 approved product(s) across US/EU regulatory metadata.
• 84 active pipeline program(s) linked via ClinicalTrials.gov.
• 379 US patent(s) indexed to this assignee profile.

Public regulatory, clinical, patent, and corporate records for Alnylam Netherlands. Not investment advice.

Recent activity

Latest pipeline, patent, and corporate events for Alnylam Netherlands.

1. Jun 8, 2026 Clinical update

   ALN-APP-001 — Phase 1

2. Jun 8, 2026 Clinical update

   ALN-TTRSC04-004 — Phase 3

3. Jun 8, 2026 Clinical update

   ALN-AGT01-008 — Phase 3

4. Jun 8, 2026 Clinical update

   ALN-TTRSC02-003 — Phase 3

5. Jun 8, 2026 Clinical update

   ALN-TTRSC02-002 — Phase 3

View all clinical trial activity →

• What is Alnylam Netherlands?

  Alnylam Netherlands is a pharma organization headquartered in Cambridge, USA. It trades on NYSE under ticker ALNY. Primary therapeutic focus areas include TTR-mediated Amyloidosis, Hypertension, Transthyretin Amyloidosis, Type 2 Diabetes Mellitus (T2DM), Acute Intermittent Porphy

• Is Alnylam Netherlands publicly traded?

  Yes. Alnylam Netherlands is listed with ticker ALNY on NYSE per SEC EDGAR records linked on this profile.

• What drugs does Alnylam Netherlands develop or market?

  We link 37 drug profile(s) where Alnylam Netherlands is an originator or marketer in FDA or regional approval metadata. See the drug portfolio table on https://novapharmanews.com/companies/alnylam-pharmaceuticals-inc#company-drugs.

• What are the latest developments for Alnylam Netherlands?

  In the last 12 months our linked public records show 84 trial program update(s) and 11 US patent grant(s) tied to this profile.

• What therapeutic areas does Alnylam Netherlands focus on?

  Alnylam Netherlands focuses on TTR-mediated Amyloidosis, Hypertension, Transthyretin Amyloidosis based on our analysis of their pipeline programs and drug development activities.